NCT05127122View on ClinicalTrials.gov

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
ARDS, Human
Interventions
DRUG

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles

Injectable

OTHER

Saline

Placebo Saline

Sponsors
All Listed Sponsors
lead

Direct Biologics, LLC

INDUSTRY